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Objectives: Mitral valve repair is the standard therapy for patients with degenerative
(myxomatous) disease and severe mitral regurgitation. Robotic mitral valve repair
provides the least-invasive surgical approach. We report the largest single-center
robotic mitral valve repair experience.
Methods: Between May 2000 and November 2006, 300 patients underwent a robotic
mitral valve repair (daVinci Surgical System; Intuitive Surgical, Inc, Sunnyvale,
Calif). All operations were done with 3- to 4-cm right intercostal access, transthoracic
aortic occlusion, and peripheral cardiopulmonary bypass. Repairs included 1 or a com-
bination of trapezoidal/triangular leaflet resections, sliding plasties, chordal transfers/
replacements, edge-to-edge approximations, and ring annuloplasties. Echocardio-
graphic and survival follow-up were 93% and 100% complete, respectively.
Results: There were 2 (0.7%) 30-day mortalities and 6 (2.0%) late mortalities. No
sternotomy conversions or mitral valve replacements were required. Immediate post-
repair echocardiograms showed the following degrees of mitral regurgitation: none/
trivial, 294 (98%); mild, 3 (1.0%); moderate, 3 (1.0%); and severe, 0 (0.0%). Compli-
cations included 2 (0.7%) strokes, 2 transient ischemic attacks, 3 (1.0%) myocardial
infarctions, and 7 (2.3%) reoperations for bleeding. The mean hospital stay was 5.26
4.2 (standard deviation) days. Sixteen (5.3%) patients required a reoperation. Mean
postoperative echocardiographic follow-up at 815 6 459 (standard deviation) days
demonstrated the following degrees of mitral regurgitation: none/trivial, 192
(68.8%); mild, 66 (23.6%); moderate, 15 (5.4%); and severe, 6 (2.2%). Five-year
Kaplan–Meier survival was 96.6% 6 1.5%, with 93.8% 6 1.6% freedom from
reoperation.
Conclusions: Robotic mitral valve repair is safe and is associated with good midterm
durability. Further long-term follow-up is necessary.
M
itral valve repair (MVP) surgery has advanced markedly over the past 25
years.1-4 Excellent long-termMVP outcomes, compared with prosthetic re-
placements, have shifted the focus of patients, cardiologists, and surgeons
toward improving repair techniques, including less-invasive access. In the last 10
years, minimally invasiveMVPs for patients with degenerative (myxomatous) disease
have been similar to or better than those yielded by traditional sternotomy oper-
ations.5-11 Minimally invasive repairs with nonrobotic endoscopic approaches have
been described.5,8,9 Few surgeons have demonstrated success in complex combined
leaflet, annular, and chordal repairs by using these techniques due, in part, to the
ergonomic difficulties associated with long manual instruments and limited operative
precision in space-limited cardiac chambers. This report describes the clinical out-
comes in 300 patients who underwent MVP with advanced robotic technology.
In this setting articulated instrumentation enables robotic tissue telemanipulation
coupled with high-definition, 3-dimensional secondary vision.
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FDA 5 US Food and Drug Administration
MR 5 mitral regurgitation
MV 5 mitral valve
MVP 5 mitral valve repair
TEE 5 transesophageal echocardiography
TTE 5 transthoracic echocardiography
Materials and Methods
Study Population
Between May 2000 and November 2006, 300 patients underwent
MVP at the University Health System of Eastern Carolina and
East Carolina University with the da Vinci robotic surgical system
(Intuitive Surgical, Inc, Sunnyvale, Calif). During the same time
period, an additional 646 mitral valve (MV) operations were
performed at our center either through a sternotomy or right mini-
thoracotomy with videoscopic assistance. Study protocols were
approved by the University Health System of Eastern Carolina Insti-
tutional Review Board, and informed consent was obtained from
each patient. All patients with degenerative MV disease were
considered to be candidates for a robotic repair. Exclusion criteria
included an extensively calcified MV annulus, preoperative
planning for an MV replacement, severe pulmonary hypertension
(pulmonary artery systolic pressure.70 mm Hg), poor left ventric-
ular function (ejection fraction ,20%), and significant coronary
artery disease necessitating multivessel bypass grafting.
Routine preoperative evaluations included a history and physical
examination, chest radiography, and 12-lead electrocardiography.
In patients older than 40 years, either angiography or computed to-
mography was used to rule out significant coronary disease. Every
patient underwent either preoperative transthoracic echocardiogra-
phy (TTE) or transesophageal echocardiography (TEE).
Operative Technique
Two-dimensional TEE with a color flow Doppler study was per-
formed in the operating room to confirm the plan for each mitral re-
construction. Acquired images included 4-chamber views, as well as
short- and long-axis 2-chamber views, at both the midesophageal
and deep transgastric levels. Preoperative and postoperative right
and left ventricular function were assessed at midchamber in the
short-axis dimension. Operations were conducted through a 3- to
4-cm right inframammary incision through the fourth or fifth inter-
costal space, as well as three 1-cm robotic arm ports placed radially
around the incision. After the instrument arms were inserted, stan-
dard repair techniques were used for leaflet resections and recon-
structions, chordal procedures (including chordal transfers), and
polytetrafluorethylene neochordal construction*, and all-suture
knot tying was done intracorporeally with the robotic arms. In every
case an annuloplasty was performedwith a Cosgrove–Edwards band
(Edwards Lifesciences, Irvine, Calif) secured either with 2-0 Cardio-
flon sutures (Peters, Inc, Paris, France) or nitinol U-clips (Medtronic,
Inc, Minneapolis, Minn).
*Gore-Tex neochord, W. L. Gore % Associates, Inc, Newark, Del.The Journal of ThorCardiopulmonary bypass was established through femoral vessel
cannulation. Cold (4C) antegrade crystalloid cardioplegia and
a transthoracic aortic crossclamp (Scanlan International, Minneapo-
lis, Minn) provided myocardial protection during the arrest period.
All mitral repairs were performed by a single operative console sur-
geon; however, multiple patient-side surgeons participated. More
details of our robotic operative approach and repair techniques
have been published previously.11-13
Follow-up Evaluation
All surviving patients were examined and evaluated 6weeks postop-
eratively. Our recommended echocardiographic follow-up includes
TTE done between 3 and 6months after surgical intervention and an-
nually thereafter. Interval clinical follow-up was done through direct
contact with patients, their referring physicians, or both or through
queries of social security number and national death registries.
Data Collection and Statistical Methods
All perioperative and outcomes data were collected contemporane-
ously into a proprietary clinical cardiovascular information system.
Data are expressed as means6 SD. The Kaplan–Meier curves were
calculated by using R version 2.41 (http://www.r-project.org).
Results
Patient Characteristics
Table 1 lists preoperative demographic information for all pa-
tients. Participants were enrolled consecutively, and the first
20 patients constituted a phase I US Food and Drug Admin-
istration (FDA) safety and efficacy trial (G000023).11 The
next 22 patients were included in a phase II FDA multicenter
trial (G000295).12 The remaining patients had repairs done
after FDA approval of the da Vinci surgical system for use
in intracardiac surgery.
Operative Data
During this time period, 309 patients underwent an intent-to-
treat robotic MVP. There were no intraoperative conversions
to a sternotomy. A total of 9 cases were converted to a mini-
mally invasive approach by using the same incision and vid-
eoscopic assistance. The reasons for these conversions
included early da Vinci systemmalfunction (n5 3), poor sur-
gical exposure (n5 4), external instrument conflicts (n5 1),
and need for MV replacement (n 5 1).
Table 2 shows the variety of repair techniques used in this
series, ranging from simple annuloplasty bands with or with-
out a leaflet resection to more complex repairs involving
chordal transfers (n 5 81), polytetrafluoroethylene neochor-
dal implantations (n5 48), and a combination of chordal pro-
cedures (n5 23) for the management of Barlows disease and
anterior leaflet prolapse pathologies. Also shown are con-
comitant procedures and cardiopulmonary bypass times.
Mortality and Morbidity
In this series of 300 robot-assisted cases, there were no intra-
operative device– or perfusion-related patient complications.acic and Cardiovascular Surgery c Volume 136, Number 2 437
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were 2 (0.7%) deaths within 30 days, one related to a prot-
amine reaction and the other to right ventricular failure. In ad-
dition, there were 6 (2.0%) late mortalities. Four of these
patients died from noncardiac causes. Two patients died after
MV reoperations: one died from a stroke and multiorgan fail-
ure, and the other died from ventricular failure.
The mean intensive care unit length of stay was 32.4 6
67.3 hours, with 286 (95.3%) patients extubated within 24
hours. The mean hospital stay was 5.2 6 4.2 days, with
58.3% of patients discharged by postoperative day 4.
Thirty-five (11.7%) patients were readmitted within 30 days
of the operation for respiratory problems (n 5 13), atrial
arrhythmias (n 5 6), pericarditis (n 5 2), syncope (n 5 2),
valve dysfunction (n 5 4), or other causes (n 5 8).
Reoperation was required in 16 (5.3%) patients at a mean
of 3196 327 days (range, 15–946 days) from the original op-
eration. Eight reoperations occurred within 71 days (mean,
42 6 24 days) of the original operation, and the remaining
8 occurred after 305 days (mean 596 6 230 days). Seven
TABLE 1. Preoperative demographics
Characteristics
Age (y), mean 6 SD 56.5 6 12.8
Age (y), range 19–80
Female sex 107 (35.7)
Body mass index, mean 6 SD 25.7 6 4.1
New York Heart Association
Class I 55 (18.3)
Class II 167 (55.7)
Class III 74 (24.7)
Class IV 4 (1.3)
Comorbidities
Congestive heart failure 242 (80.7)
Hypertension 120 (40.0)
Smoking history 102 (34.0)
Diabetes 19 (6.3)
Renal insufficiency 1 (0.3)
Pulmonary hypertension 49 (16.3)
Atrial fibrillation/atrial flutter 54 (18.0)
Coronary artery disease 26 (8.7)
Peripheral vascular disease 3 (1.0)
Stroke 8 (2.7)
Previous cardiac surgery 2 (0.7)
Echocardiographic details
LVEF, mean 6 SD 57.8 6 8.5
.45% 269 (89.7)
35%–45% 25 (8.3)
25%–35% 5 (1.7)
20%–25% 1 (0.3)
Severe mitral insufficiency 272 (90.7)
Severe tricuspid insufficiency 1 (0.3)
Values are presented as number (percentage), where shown. SD, Standard
deviation; LVEF, left ventricular ejection fraction.438 The Journal of Thoracic and Cardiovascular Surgery c Aufailures were within the first 100 operations, and 9 occurred
among the last 200 operations.
Reasons for reoperation included progression of native
disease (n5 3), valve endocarditis (n5 1), or technical fail-
ures (n5 10); these included anterior leaflet systolic anterior
motion (n5 2). Technical failures included 7 patients having
a band dehiscence, with 4 (or 4%) among the first 100 cases
but only 3 (or 1.5%) among the last 200 cases. In the groups
undergoing reoperations, a prosthetic valve replacement
was performed in 13 patients, and rerepair was possible in 3
individuals. The extent of immediate postoperative mitral re-
gurgitation (MR) for the 16 patients undergoing reoperations
ranged from none (n5 10) to trace (n5 5) tomild tomoderate
(n 5 1).
Echocardiographic Studies and Patient Follow-up
As demonstrated in Table 4, all 300 patients underwent intra-
operative postrepair TEE, with 280 (93.3%) patients having
no MR. Follow-up TTE studies were obtained in 279 (93%)
patients, with a mean follow-up of 8156 459 days. Reasons
for failure to obtain follow-up TTE studies included patient re-
fusal to participate in the study (n5 8), early death (n5 2), or
loss of direct patient contact (n 5 11). Follow-up TTE re-
vealed the following degrees of MR: none to trace (n5 192,
68.8%), mild (n 5 66, 23.6%), moderate (n 5 15, 5.3%),
and severe (n5 6, 2.2%). Every one of the patientswith severe
MR during follow-up has undergone a reoperation.
TABLE 2. Operative details
Mitral valve repair type
Annuloplasty band 300 (100)
Median size (range, 26–40 mm) 32 mm
Annuloplasty alone 40 (13.3)
Edge-to-edge 1 annuloplasty 6 (2.0)
Leaflet resection 1 annuloplasty 72 (24.0)
Leaflet resection 1 sliding plasty with
or without chordal procedure 1 annuloplasty
75 (25.0)
Chordal procedure (no leaflet resection)
1 annuloplasty
40 (13.3)
Leaflet resection 1 chordal procedure
1 annuloplasty
60 (20.0)
Leaflet repair 1 annuloplasty 7 (2.3)
Concomitant procedures
CryoMaze atrial fibrillation ablation 31 (10.3)
Radiofrequency or microwave atrial
fibrillation ablation
22 (7.3)
Patent foramen ovale closure 33 (11)
Atrial septal defect closure 1 (0.3)
Minimally invasive coronary artery bypass 2 (0.7)
Perfusion details
Cardiopulmonary bypass time (min), mean 6 SD 158.7 6 41.8
Crossclamp time (min), mean 6 SD 122.1 6 33.3
Values are presented as number (percentage), where shown. SD, Standard
deviation.gust 2008
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6 623 days. Five-year Kaplan–Meier survival and freedom
from reoperation rates were 96.6% 6 1.5% and 93.8% 6
1.6%, respectively (Figure 1).
Discussion
We report the largest single-center series to date of robotic
MVP. In this study we demonstrate that these procedures
can be performed safely and with excellent results.
Since Carpentier’s 1983 ‘‘French correction’’ article14
demonstrating the benefits of performing a functional mitral
repair rather than a valve replacement, there has been
a steadily increasing interest in mitral reconstruction in North
America. Compared with prosthetic replacements, repairs
increased survival and minimized thromboembolism, endo-
carditis, and anticoagulation-related complications. Carpent-
ier, Cosgrove, and David each showed a 92% to 95%
reoperative freedom with repairs when performed through
a traditional sternotomy.1,15-18 These benefits convinced car-
diologists and surgeons alike to recommend mitral repair for
symptomatic patients with significant MR from degenerative
(myxomatous) disease.
A variety of minimal-access approaches have been devel-
oped to perform MVPs, including limited sternotomies and
videoscopicminithoracotomies (3-4 cm) using 2-dimensional
TABLE 3. Postoperative outcomes and complications
30-d Mortality 2 (0.7)
Late mortality 6 (2.0)
Myocardial infarction 3 (1.0)
Stroke (minor) 2 (0.7)
Reversible neurologic injury 2 (0.7)
Prolonged mechanical ventilation (.48 h) 7 (2.3)
Bleeding requiring reoperation 7 (2.3)
Any blood product transfusion 87 (29.0)
pRBC 46 (15.3)
FFP 20 (6.7)
Platelets 23 (7.7)
Infection 1 (0.3)
Renal insufficiency 6 (2.0)
Atrial fibrillation/atrial flutter 83 (27.7)
Pleural effusion 28 (9.3)
Aortic dissection 0 (0)
Femoral arterial or vein complication 0 (0)
Hospital length of stay (d), mean 6 SD 5.2 6 4.2
Readmission within 30 d 35 (11.7)
Long-term repair failures and second operation
Mitral valve replacement 13 (4.3)
Mitral valve rerepair 3 (1.0)
Values are presented as number (percentage), where shown. pRBC, Packed
red blood cells; FFP, fresh frozen plasma; SD, standard deviation.
TABLE 4. Echocardiographic data
Preoperative,
n 5 300 (%)
After repair,
n 5 300 (%)
Follow-up,
n 5 279 (%)
MR severity
None 0 (0) 280 (93) 125 (44.8)
Trace 0 (0) 12 (4) 67 (24)
Mild 0 (0) 5 (1.6) 66 (23.6)
Moderate 28 (9.3) 3 (1) 15 (5.3)
Severe 272 (90.7) 0 (0) 6 (2.2)
MR, Mitral regurgitation.
Figure 1. A, Kaplan–Meier survival curve. Dotted lines, Confi-
dence interval. Patients at risk at each year are also shown. B,
Kaplan–Meier freedom from reoperation. Dotted lines, Confidence
interval. Patients at risk at each year are also shown.
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reported a large series of videoscopic MVPs andMV replace-
ments with lower 3.6% reoperative rates. At our institution,20
since 1996, 514mitral repairs or replacements have been done
by using this method, with results similar to those of Vaner-
men and colleagues. These patients either preceded our adop-
tion of robotic techniques or met our exclusion criteria for
using the da Vinci system.With this video-assisted approach,
however, significant ergonomic and visual limitations persist,
in particular related to complex mitral repairs involving
chordal transfer, sliding valvuloplasty, and partial leaflet
transposition. Performance of a truly endoscopic mitral repair
through thoracic ports requires 3-dimensional visualization
and articulated instrumentation for these complex cases.
The da Vinci robotic surgical system enables surgeons to
perform complex mitral repairs through port incisions using
optimized, high-definition visualization and fine dexterity.21
Through magnified telepresence, the operator becomes en-
sconced in the anatomic landscape without distraction while
instrument tips are telemanipulated through 7 degrees of
ergonomic freedom. Ambidextrous access to the entire
subvalvular chordal apparatus and papillary muscles, as
well as all leaflet topography, becomes possible without in-
strument-tip tremor. Both digital and analog camera zooming
make visualization interactive, and dynamic foot-clutch in-
strument realignment further enables optimal hand position
for maximal ergonomic access to the operative zone.
Carpentier and associates22 and Autschbach and col-
leagues23 first used prototypes of this robotic device in
1998 to perform mitral repairs. Beginning in 2000, 2 FDA
investigational device trials provided the pathway for 2002
approval for intracardiac use in the United States. This report
details midterm clinical results from 300 consecutive daVinci
Surgical SystemMVPs, including patients from the inaugural
FDA studies.11,12 In this single-center experience 245 repairs
involved more than a simple annuloplasty ring, edge-to-edge
repair, or both, and 52 (17.3%) were for bileaflet prolapse.
With this approach, the transfusion requirements and lengths
of stay in the hospital are similar to those of other robotic re-
pair series; Woo and Nacke24 reported blood product transfu-
sion rates, with 15.3% requiring packed red blood cell
transfusions. In addition, rates of re-exploration for bleeding
compare favorably with those for minithoracotomy and hem-
isternotomy mitral repair series.19,25 Furthermore, 58% and
75% of patients in the present series were discharged by post-
operative days 4 and 5, respectively, with a readmission rate
of only 11%. In contrast, Tatooles and associates26 reported
a mean hospitalization of only 2.7 days; however, patients
in their study experienced a 28% readmission rate.
In the current series 5.3% of patients required a reoperation
within 2 years (mean, 319 6 353 days). These results are
similar to those of the FDAmulticenter trial11,12 and compare
favorably with results of several sternotomy-based series,
which reported 5% to 6% early repair failures.1-3,16 Video440 The Journal of Thoracic and Cardiovascular Surgery c Aureview of the primary operation was done for all failed repairs.
Reoperations were found to result from either technical causes
or disease progression. Seven patients had an annuloplasty
ring dehiscence, which occurred primarily at the right fibrous
trigone and posterior commissure. Early in the series, a rigid
transthoracic retractor was used for exposure, which prevented
optimal access to this area. It is likely that instrument retraction
and multiple annular suture passes weakened the tissuematrix,
thus resulting in dehiscence. Annuloplasty band failures were
balanced between clip and suture fixation. Two patients had
incomplete reduction of the posterior leaflet, eventuating in re-
fractory anterior leaflet septal motion. In patients with disease
progression undergoing reoperation, 2 reoperations failed be-
cause of recurrent annular dilatation with return of central re-
gurgitation, and 1 patient had progressive bileaflet prolapse.
A detailed reviewed of the nature of these reoperations will
be discussed in a separate publication27.
Temporally, 7 failures occurred among the first 100 cases
(7% failure rate); early on, the lack of tactile feedback could
have initially limited the ability to assess suture depth and ten-
sion, resulting in repair failure. Developments in robotic tech-
nology, such as an articulated robotic atrial retractor, which
provides ideal anatomic exposure to allmitral regions, and im-
aging improvements that permitmagnified and 3-dimensional
vision and surrogate feedback that projects ‘‘visual tactility,’’
now enable surgeons to understand tissue deformational char-
acteristics and suture remodeling with tightening. This might
have contributed to the improved 4.5% (n 5 9) failure rate
that was observed among the next 200 cases. Clearly, experi-
ence gained over the 6-year study duration resulted in the per-
formance of more complex repairs done with greater facility
and fewer failures.13 We anticipate that use of 3-dimensional
TEE for intraoperative planning and analysis will contribute
to further improvements in these results.
There are several important limitations to this study. First,
this is a single-center observational analysis without an ade-
quate comparison sternotomy experience other than historical
data. Although patients had the option of having a traditional
sternotomy-based operation, most were referred specifically
for a minimally invasive operation, which precluded the
option of randomization.
Second, follow-up echocardiograms were not interpreted
by a single echocardiographer. Because approximately 40%
of our patients are from out of the state of North Carolina,
we had to rely on the patient’s local cardiologist for echocar-
diographic follow-up.
Finally, longer-term follow-up is necessary to fully assess
whether robotic MVP is equivalent to or better than the tradi-
tional sternotomy-basedMVP approach. As a continuous ob-
servational series, however, inclusion of FDA trial data (first
cases done in the United States), continuation as a consecu-
tive series, prospective protocol planning, contemporaneous
data collection, and 93% echocardiographic follow-up add
strength to this prospective study.gust 2008
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surgery has followed the typical technology adoption se-
quence, with early enthusiasm, early failures, and then more
experience leading to improved performance by some sur-
geons. Controlled application by experienced surgeons re-
mains the ideal way to initiate new technology in a safe and
efficacious manner. We have demonstrated that complex
repairs of theMV can be done endoscopically through robotic
surgical telemanipulation, with excellent results. These re-
pairs are durable out to an intermediate term; continued
follow-up will be important for establishing the long-term
efficacy of robotic MV operations. Until then, we anticipate
that this study will serve as a springboard for further develop-
ment and application of robotic cardiac surgery.
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Simon C. Moten, MD; and Karen Gersch, MD).
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